At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
Xeomin Injectable Productdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Évaluation de l'Effet d'Injections répétées de Hautes Doses de Toxine Botulique Dans le Membre inférieur de Sujets cérébrolésés Spastiques Sur Les paramètres Fonctionnels et biomécaniques de Marche
Cliniques universitaires Saint-Luc- Université Catholique de Louvain·interventional·Posted Sep 10, 2020·Updated Aug 15, 2023
In Brief
A clinical study evaluating Xeomin Injectable Product for Stroke. Completed, enrolled 32 participants across 2 sites.
Detailed Summary
1. To show that repeated injections of higher doses of botulinum toxin are significantly more effective than the injection of unique, lower doses, on gait function. 2. To describe the effect of repeated injections of botulinum toxin on the muscle structure in terms of volume, fat accumulation and fibrosis, by means of MRI studies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
First PostedSep 2020
Primary CompletionDec 2021
TodayJul 2026
First PostedSep 10, 2020
Enrollment StartSep 13, 2018
Primary CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.8 years ago
Interventions
Xeomin Injectable Productdrug
Intramuscular injection